ReviewVascular health and risk management2016
Targeting heart failure with preserved ejection fraction: current status and future prospects.
Review in Vascular health and risk management, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between the beta-blockers, calcium channel blockers, all-cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.Clinical cardiology · 2023Pooled it
- The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone.British journal of clinical pharmacology · 2025Article
- Article
- Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.Drugs in context · 2023Review
- Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies.Biomedicines · 2022Review
- DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.Journal of diabetes and its complications · 2022Review
- Carvedilol and exercise combination therapy improves systolic but not diastolic function and reduces plasma osteopontin inAmerican journal of physiology. Heart and circulatory physiology · 2021Article
- Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis.Circulation. Heart failure · 2020Article
- Heart Failure with Preserved Ejection Fraction-a Concise Review.Current cardiology reports · 2020Review
- Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities.Basic research in cardiology · 2020Review
- Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020Review
- Motivational interviewing can support physical activity in elderly patients with diastolic heart failure: results from a pilot study.ESC heart failure · 2019Article
- Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2018Article
- Quantification of Biventricular Strains in Heart Failure With Preserved Ejection Fraction Patient Using Hyperelastic Warping Method.Frontiers in physiology · 2018Article
- Reducing RBM20 activity improves diastolic dysfunction and cardiac atrophy.Journal of molecular medicine (Berlin, Germany) · 2016Article
- Heat-killed Lactobacillus Reuteri GMNL-263 Prevents Epididymal Fat Accumulation and Cardiac Injury in High-Calorie Diet-Fed Rats.International journal of medical sciences · 2016Article
- Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction.JACC. Basic to translational scienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) portrays a significant burden in terms of prevalence, morbidity, mortality, and health care costs. There is a lack of consensus on the basic pathophysiology, definition, and therapeutic targets for therapy for this syndrome. To date, there are no approved therapies available for reducing mortality or hospitalization for these patients. Several clinical trials have recently started to try and bridge this major gap. There is an urgent need to focus on drug and device development for HFpEF as well as to understand HFpEF pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.